~~<i id='7617237866'><strike id='7617237866'><tt id='7617237866'><pre id='7617237866'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：knowledge 2025-09-06 05:01:19 Page View：9995

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Judges halt a Biden rule offering student debt relief for those alleging colleges misled them
Next article： Alkermes shareholders re

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

MollyFerguson/STATThisweek,apreviewoftheTUDCAstudyinALSandthoughtsonhowitmightimpactAmylyxPharmaceut

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Ebola vaccine can save some who are already sick, per new study

Anewstudyshowsthatinadditiontopreventinginfections,theEbolavaccinecansavesomepeoplewhoarealreadysick